Immunome (IMNM) EBIAT (2023 - 2025)
Historic EBIAT for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$57.5 million.
- Immunome's EBIAT fell 2198.94% to -$57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.7 million, marking a year-over-year increase of 2705.27%. This contributed to the annual value of -$293.0 million for FY2024, which is 17429.45% down from last year.
- As of Q3 2025, Immunome's EBIAT stood at -$57.5 million, which was down 2198.94% from -$43.4 million recorded in Q2 2025.
- In the past 5 years, Immunome's EBIAT registered a high of -$4.3 million during Q1 2023, and its lowest value of -$129.5 million during Q1 2024.
- Its 3-year average for EBIAT is -$49.3 million, with a median of -$43.4 million in 2025.
- Per our database at Business Quant, Immunome's EBIAT crashed by 293259.95% in 2024 and then surged by 6784.36% in 2025.
- Immunome's EBIAT (Quarter) stood at -$92.6 million in 2023, then grew by 13.37% to -$80.2 million in 2024, then increased by 28.4% to -$57.5 million in 2025.
- Its EBIAT stands at -$57.5 million for Q3 2025, versus -$43.4 million for Q2 2025 and -$41.6 million for Q1 2025.